Outcomes of proton therapy for non-small cell lung cancer in patients with interstitial pneumonia.

Shingo HashimotoHiromitsu IwataYukiko HattoriKoichiro NakajimaKento NomuraKensuke HayashiToshiyuki ToshitoEiko YamamoriKenji AkitaJun-Etsu MizoeHiroyuki OginoYuta Shibamoto

Published in: Radiation oncology (London, England) (2022)

PT may be a relatively safe treatment for NSCLC patients with IP, without deteriorating quality of life scores within 3 months.

Keyphrases

small cell lung cancer
skeletal muscle
insulin resistance
weight loss
respiratory failure
replacement therapy
tyrosine kinase
epidermal growth factor receptor
glycemic control